Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant

Thumbnail
View/Open
Date
2017-04-06
ICR Author
Author
Hiwarkar, P
Amrolia, P
Sivaprakasam, P
Lum, SH
Doss, H
Type
Journal Article
Metadata
Show full item record
Abstract
Key Points Brincidofovir has superior antiadenoviral activity and safety profile compared with cidofovir. Brincidofovir is highly efficacious in controlling adenoviremia during the lymphopenic phase of HCT.
URI
https://repository.icr.ac.uk/handle/internal/1534
DOI
Collections
Language
eng
License start date
2017-04-06
Citation
Blood, 2017, 129 (14), pp. 2033 - 2037
Publisher
American Society of Hematology